-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Written byWang Cong
EditorWang Duoyu
TypesettingWater into writing
Recently, Replimune reported the results
of its oncolytic viral therapy RP2 as a monotherapy or in combination with the PD-1 inhibitor nivolumab (nivolumab) in the treatment of advanced solid tumors at the annual meeting of the European Society for Internal Oncology (ESMO).
RP2 is an oncolytic virus therapy based on herpes simplex virus (HSV-1) developed by Replimune
.
Replimune is a NASDAQ-listed clinical-stage immunotherapy development company with a current market capitalization of $779 million
.